MedTrace Logo

Medications Development for the Treatment of Cannabis Related Disorders

NCT01204723 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2012-06-01

No results posted yet for this study

Summary

The primary objective of this application is to test the neurobehavioral mechanisms and effects of aprepitant as a new cessation agent for cannabis, tobacco or both.

Conditions

  • Nicotine Withdrawal
  • Marijuana Dependence
  • Cannabis Dependence
  • Nicotine Dependence
  • Cannabis Abuse

Interventions

DRUG

Placebo Aprepitant

Placebo Aprepitant 0 mg once daily for 5 days

DRUG

Active Aprepitant

Active Aprepitant 160 mg once daily for 5 days

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • University of Virginia

    lead OTHER

Principal Investigators

  • Heather M Haughey, Ph.D. · University of Virginia School of Medicine, Dept. Psychiatry and Neurobehavioral Sciences

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2012-01-31
Completion
2012-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01204723 on ClinicalTrials.gov